MOLECULAR SUBTYPES IN LEIOMYOSARCOMA Matt van de Rijn, Stanford University Xiangqian Guo 1, Vickie Young Jo 2, Anne M. Mills 3,Shirley X Zhu 1, Cheng-Han.

MOLECULAR SUBTYPES IN LEIOMYOSARCOMA

Matt van de Rijn, Stanford University

Xiangqian Guo1, Vickie Young Jo2, Anne M. Mills3,Shirley X Zhu1, Cheng-Han Lee4, Inigo Espinosa5, Sushama Varma1, Erna Forgó1, Trevor Hastie6,

Kristen Ganjoo7, Andrew H. Beck8, Robert B West1, Christopher Fletcher2, Matt van de Rijn1

1 Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA

2 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, 02115, USA3 Department of Pathology, University of Virginia, Charlottesville, VA, 22904, USA

4 Division of Anatomical Pathology, Royal Alexandra Hospital, Edmonton, Alberta, Canada5 Department of Pathology, Autonomous University of Barcelona, Barcelona, Spain

6 Department of Statistics, Stanford University, Stanford, CA, 94305, USA7 Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, 94305, USA

8 Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA

Unbiased search for subtypes

- - gene expression profiling of frozen tissues of 51 LMS cases using gene arrays (Oncogene. 2010:29:845-54)

- - 3 subtypes, immunohistochemistry markers for one subtype

New data: FFPE-compatible next generation sequencing approach “3SEQ” on 99 cases of LMS

Similar results in analysis of 82 LMS TCGA dataset

Comparison of 3SEQ and TCGA dataset

3SEQ

TCGA

70 “core” cases of LMS

70 “core” cases

Type 1-LM/myometrium, Type II-UPS

IHC markers

Subtype assigned by IHC on outcome TMA

Subtype assigned by IHC on outcome TMA

Gene Therapeutic Agents Genes over-expressed in subtype I ARAF Sorafenib, Vemurafenib, Dabrafenib, RAF inhibitors CCNE1 CKD2 inhibitor KDR KDR inhibitors NOTCH1 Notch Inhibitors FGFR2 FGFR Inhibitors FGFR1 FGFR Inhibitors Genes over-expressed in subtype II MCL1 Tubulins CDK4 CDK4/6 inhibitors CTNNB1 WNT inhibitors AURKA AURKA Inhibitors RHEB MTOR inhibitors CCND2 CDK4/6 inhibitors CCND1 Hormone therapy, CDK4/6 inhibitors MTOR Everolimus, Temsirolimus, MTOR inhibitors MAPK3 Erlotinib, Gefitinib, EGFR Inhibitors MAPK1 Erlotinib, Gefitinib, EGFR Inhibitors CCND3 CDK4/6 inhibitors NOTCH2 Notch Inhibitors MAP2K2 MEK inhibitors Genes over-expressed in subtype III MDM4 MDM4 inhibitors ERBB3 Pertuzumab EPHA3 Dasatinib, Ephrin inhibitors ESR1 Hormonal therapy Genes over-expressed in subtype II and III EGFR Erlotinib, Gefitinib, EGFR Inhibitors

Targets unique to LMS subtypes

Conclusions

• An unbiased search reveals at least 3 molecular subtypes in LMS

• Found in 3 independent datasets with 3 distinct methods

• Subtypes independent from grade, site• Subtypes show different clinical behavior• Findings suggest different response to range of

novel drugs